American Journal of Ophthalmology
Volume 140, Issue 2 , Pages 242.e1-242.e11 , August 2005

Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension

  • Joel S. Schuman, MD

      Affiliations

    • UPMC Eye Center, Eye and Ear Institute, Pittsburgh, Pennsylvania
    • Corresponding Author InformationInquiries to Joel S. Schuman, MD, UPMC Eye Center, University of Pittsburgh School of Medicine, Eye and Ear Institute, 203 Lothrop Street, Suite 816, Pittsburgh, PA 15213; fax: (412) 647-5119
    • ,
  • Gregory J. Katz, MD

      Affiliations

    • private practice, Ypsilanti, Michigan
    • ,
  • Richard A. Lewis, MD

      Affiliations

    • private practice, Sacramento, California
    • ,
  • J. Charles Henry, MD

      Affiliations

    • private practice, Little Rock, Arkansas
    • ,
  • Sushanta Mallick, PhD

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.
    • ,
  • David T. Wells, BSN

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.
    • ,
  • E. Kenneth Sullivan, PhD

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.
    • ,
  • Theresa A. Landry, PhD

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.
    • ,
  • Michael V.W. Bergamini, PhD

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.
    • ,
  • Stella M. Robertson, PhD

      Affiliations

    • Alcon Research Ltd, Fort Worth, Texas.

,Accepted 28 February 2005.

References 

  1. Zimmerman TJ , Kaufman HE . Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma . Arch Ophthalmol . 1977;95:601–604
  2. Quigley HA . Open-angle glaucoma . N Engl J Med . 1993;328:1097–1106
  3. Coakes RL , Brubaker RF . The mechanism of timolol in lowering intraocular pressure . Arch Ophthalmol . 1978;96:2045–2048
  4. Gabelt B , Kaufman P . Prostaglandin F2α increases uveoscleral outflow in the cynomologus monkey . Exp Eye Res . 1989;49:389–402
  5. Nilsson S , Samuelsson M , Bill A , et al.   Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomologus monkey . Exp Eye Res . 1989;48:707–716
  6. Crawford K , Kaufman P . Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys (evidence for enhancement of uveoscleral outflow by prostaglandin F2α) . Arch Ophthalmol . 1987;105:1112–1116
  7. Camras CB . Mechanism of the prostaglandin-induced reduction of intraocular pressure in human . Adv Prostaglandin Thromboxane Leukot Res . 1995;23:519–525
  8. Netland PA , Landry T , Sullivan EK , et al.   Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension . Am J Ophthalmol . 2001;132:472–484
  9. AGIS Investigators . The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration . Am J Ophthalmol . 2000;130:429–440
  10. Kass MA , Heuer DK , Higginbotham EJ , et al.   The Ocular Hypertension Treatment Study (a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma) . Arch Ophthalmol . 2002;120:701–713
  11. Grant WM , Burke JF . Why do some people go blind from glaucoma? . Ophthalmology . 1982;89:991–998
  12. Zimmerman TJ . Topical ophthalmic beta-blockers (a comparative review) . J Ocular Pharm . 1993;9:373–384
  13. Crider JY , Sharif NA . Adenylyl cyclase activity mediated by β-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells . J Ocular Pharm Ther . 2002;18:221–230
  14. Eisenberg DL , Toris CB , Camras CB . Bimatoprost and travoprost (a review of recent studies of two new glaucoma drugs) . Surv Ophthalmol . 2002;47:S105–S115
  15. Weinreb RN , Toris CB , Gabelt BT , Lindsey JD , Kaufman PL . Effects of prostaglandins on the aqueous humor outflow pathways . Surv Ophthalmol . 2002;47:S53–S64
  16. Sharif NA , Kelly CR , Crider JY . Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor . J Ocular Pharm Ther . 2002;18:313–324
  17. Kelly CR , Williams GW , Sharif NA . Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors . J Pharm Exp Ther . 2003;304:238–245
  18. Sharif NA , Kelly CR , Crider JY . Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues . Invest Ophthal Vis Sci . 2003;44:715–721
  19. Sharif NA , Crider JY , Husain S , Kaddour-Djebbar I , Ansari AR , Abdel-Latif AA . Human ciliary muscle cell responses to FP-class prostaglandin analogs (phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation) . J Ocular Pharm Ther . 2003;19:437–455
  20. Higginbotham EJ , Diestelhorst M , Pfeiffer N , Rouland JF , Alm A . The efficacy and safety of unfixed and fixed combination of latanoprost and other antiglaucoma medications . Surv Ophthalmol . 2002;47:S133–S140
  21. Patel SC , Spaeth GL . Compliance in patients prescribed eyedrops for glaucoma . Ophthalmic Surg . 1995;26:233–236
  22. Weinreb RN . Compliance with medical treatment of glaucoma . J Glaucoma . 1992;1:134–136
  23. Tsai JC , McClure CA , Ramos SE , Schlundt DG , Pichert JW . Compliance barriers in glaucoma (a systematic classification) . J Glaucoma . 2003;12:393–398
  24. Stewart WC , Garrison PM . Beta-blocker-induced complications and the patient with glaucoma (newer treatments to help reduce systemic adverse events) . Arch Intern Med . 1998;158:221–226
  25. Greenberg RN . Overview of patient compliance with medication dosing (a literature review) . Clin Ther . 1984;6:592–599
  26. Fiscella RG , Geller JL , Gryz LL , Wilensky J , Viana M . Cost considerations of medical therapy for glaucoma . Am J Ophthalmol . 1999;128:426–433
  27. Fiscella RG , Green A , Patuszynski DH , Wilensky J . Medical therapy cost considerations for glaucoma . Am J Ophthalmol . 2003;136:18–25
  28. Diestelhorst M , Larsson LI  European Fixed Combination Study Group . A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension . Br J Ophthalmol . 2004;88:199–203
  29. Strohmaier K , Snyder E , DuBiner H , Adamsons I  Dorzolamide-Timolol Study Group . The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components . Ophthalmology . 1998;105:1936–1944
  30. Merck & Company . West Point, PA: Cosopt (dorzolamide hydrochloride and timolol maleate) sterile ophthalmic solution prescribing information; 2000; Apr
  31. Bacharach J , Delgado MF , Iwach AG . Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide . J Ocular Pharm Ther . 2003;19:93–96
  32. Choudhri S , Wand M , Shields MB . A comparison of dorzolamide-timolol combination versus the concomitant drugs . Am J Ophthalmol . 2000;130:832–833
  33. Gugleta K , Orgul S , Flammer J . Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists’ offices . Curr Med Res Opin . 2003;19:330–335
  34. Serle J , Toor A , Fahim M , Polikoff L , Ellison J . The effect of varying dosing interval on the efficacy of intraocular pressure lowering drugs . Invest Ophthalmol Vis Sci . 2004;45(Suppl):971

 Supported by Alcon Research Ltd.

PII: S0002-9394(05)00285-0

doi: 10.1016/j.ajo.2005.02.058

American Journal of Ophthalmology
Volume 140, Issue 2 , Pages 242.e1-242.e11 , August 2005

Article Tools

* Image Usage & Resolution